Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

Hedge fund aims to influence CEO appointment as drugmaker battles share price slump and competition from Eli Lilly.

--Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a new chief executive following a share-price slump, according to the ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

By triggering weight loss using the likes of Ozempic, people can expect various possible changes to their appearance ...

Investing.com -- Parvus Asset Management, a London-based activist hedge fund, is acquiring a stake in Danish pharmaceutical company Novo Nordisk (NYSE: NVO ), according to The Financial Times. The ...

STARING at yet another pregnancy test, Erica Coronado was thrilled but terrified. The 36-year-old had given up hope of a baby ...

S&P 500, Eli Lilly and Company, Novo Nordisk A/S Class B, Novo Nordisk A/S. Read 's Market Analysis on Investing.com ...

Moelis threw himself into action, developing a reputation as one of the best connected bankers on Wall Street. In 2014, Moelis & Company went public and it now has a market capitalisation of more than ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...